Basic information of Il23r :
| Official Symbol of Gene | Il23r |
| Species | Mus musculus |
| Entrez Gene ID | 209590 |
| Official Full Name | interleukin 23 receptor |
| Also known as | IL-23R |
| Gene Type | protein coding |
| dbXrefs | Ensembl:ENSMUSG00000049093 AllianceGenome:MGI:2181693 |
| Map Location | 6; 6 C1 |
| Drug | AAV8 encoding the soluble sequence of IL-23R |
| Interaction Type | inhibitor |
Sample information of multiple sclerosis:
| Descent | N/A |
| Disease | EAE |
Literature information of multiple sclerosis :
| Pubmed ID | 29171419 |
| Year | 2017 |
| Title | Soluble interleukin 23 receptor gene therapy with adeno-associated vectors for the treatment of multiple sclerosis |
Results of multiple sclerosis :
| Result | Animals treated with AAV8/sIL23R showed a significant clinical improvement compared to mice treated with the null vector.This improvement was maintained stably until the end of the experiment. Subsequent immunological analysis in sIL23R treated animals showed a significant decrease in Interferon gamma (IFNγ) levels accompanied by an increase in the production of granulocyte macrophage colony-stimulating factor. |
| Mechanism/pathway | During MS neuropathology, antigen stimulated dendritic cells begin to secrete lymphocyte activator signals such as IL-23.IL-23, an interleukin member of the IL-12 family interacts with its membrane receptor to activate JAK kinases (JAK2 and TYK2) and then signal transducer and activator of transcription (STAT)3 and STAT4, whose action together with retinoid-related orphan receptor gamma t (RORγt) transcription factor leads to the differentiation and activation of the Th17 pathway. Therefore, IL-23, as a molecule involved in the stabilization and amplification of the Th17 phenotype and induction of the inflammatory response, is considered an interesting therapeutic target to treat MS. |
